Mukul Jain - Senseonics Holdings President
| SENS Stock | USD 0.59 0.11 22.92% |
President
Dr. Mukul Jain, Ph.D. is Chief Operating Officer of the Company. Dr. Jain previously served as our Vice President Operations, Quality and Regulatory from December 2015 to January 2017. Dr. Jain served as Senior Director, Quality and Regulatory of Senseonics, Incorporated from January 2012 to January 2014 and as Vice President Operations, Quality and Regulatory of Senseonics, Incorporated from January 2014 to December 2015. Prior to that, Dr. Jain held various positions at Medtronic, Inc., a medical technology and services company, from 1999 to January 2012, most recently as a senior program manager since 2017.
| Age | 51 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 20451 Seneca Meadows Parkway, Germantown, MD, United States, 20876-7005 |
| Phone | 301 515 7260 |
| Web | https://www.senseonics.com |
Senseonics Holdings Management Efficiency
The company has return on total asset (ROA) of (0.3873) % which means that it has lost $0.3873 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.458) %, meaning that it created substantial loss on money invested by shareholders. Senseonics Holdings' management efficiency ratios could be used to measure how well Senseonics Holdings manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, Senseonics Holdings' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 7.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 1.2 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Christopher MBA | Cigna Corp | N/A | |
| Lance Berberian | Laboratory of | 61 | |
| John Murabito | Cigna Corp | 62 | |
| Noelle Eder | Cigna Corp | 54 | |
| Adam PharmD | Cigna Corp | N/A | |
| Matt Perlberg | Cigna Corp | N/A | |
| Debra Kaspar | Mednax Inc | N/A | |
| Matthew Manders | Cigna Corp | 58 | |
| Eleni Zuppas | Veeva Systems Class | 54 | |
| Nicole Jones | Cigna Corp | 53 | |
| Dean Mirabella | Cigna Corp | N/A | |
| Glenn Eisenberg | Laboratory of | 63 | |
| Michael MD | Mednax Inc | N/A | |
| Stephen Farber | Mednax Inc | 49 | |
| C Richards | Mednax Inc | 50 | |
| Linda Chen | Mednax Inc | N/A | |
| Sandra Vaart | Laboratory of | 64 | |
| Peter Wilkinson | Laboratory of | 53 | |
| Mike Ashford | Mednax Inc | N/A | |
| Frederic Lequient | Veeva Systems Class | 51 | |
| MICHAEL TRIPLETT | Cigna Corp | 59 | |
Management Performance
| Return On Equity | -1.46 | ||||
| Return On Asset | -0.39 |
Senseonics Holdings Leadership Team
Elected by the shareholders, the Senseonics Holdings' board of directors comprises two types of representatives: Senseonics Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Senseonics. The board's role is to monitor Senseonics Holdings' management team and ensure that shareholders' interests are well served. Senseonics Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Senseonics Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mukul Jain, Vice President - Operations, Quality and Regulatory | ||
| Kenneth JD, General Advisor | ||
| Frederick Sullivan, Secretary CFO | ||
| Kenneth Horton, General Advisor | ||
| Timothy Goodnow, President CEO, Director | ||
| Frederick CPA, Secretary CFO | ||
| Francine MD, Chief Director |
Senseonics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Senseonics Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.46 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (5.36) % | ||||
| Current Valuation | 338.21 M | ||||
| Shares Outstanding | 595.33 M | ||||
| Shares Owned By Insiders | 4.96 % | ||||
| Shares Owned By Institutions | 10.01 % | ||||
| Number Of Shares Shorted | 41.27 M | ||||
| Price To Earning | 3.93 X | ||||
| Price To Book | 340.52 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Senseonics Stock Analysis
When running Senseonics Holdings' price analysis, check to measure Senseonics Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senseonics Holdings is operating at the current time. Most of Senseonics Holdings' value examination focuses on studying past and present price action to predict the probability of Senseonics Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senseonics Holdings' price. Additionally, you may evaluate how the addition of Senseonics Holdings to your portfolios can decrease your overall portfolio volatility.